Quick Answer
Mosaic ImmunoEngineering Inc. reported Net Income of -$922.0 thousand for fiscal year 2024.
Mosaic ImmunoEngineering Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | -$922.0K +8.6% |
-$1.01M +57.7% |
-$2.38M +35.4% |
-$3.68M -247.4% |
-$1.06M -32.8% |
-$798.5K +34.0% |
| Diluted EPS | -$0.13 +7.1% |
-$0.14 +57.6% |
-$0.33 +40.0% |
-$0.55 | $0.00 | $0.00 |
| Total Assets | $141.6K -21.1% |
$179.5K -31.3% |
$261.3K -3.0% |
$269.5K -67.1% |
$818.6K -57.5% |
$1.92M -25.4% |
| Cash and Equivalents | $115.0K -26.4% |
$156.2K -29.2% |
$220.6K -2.4% |
$226.1K -60.5% |
$571.9K -27.3% |
$787.1K -65.7% |
| Stockholders Equity | -$6.79M -15.6% |
-$5.87M -20.2% |
-$4.88M -74.5% |
-$2.80M | $0.00 -100.0% |
$1.70M -32.0% |
| R&D Expense | $183.9K -57.8% |
$435.4K -58.5% |
$1.05M -28.0% |
$1.46M | — | — |
| Operating Income | -$879.7K +37.2% |
-$1.40M +46.7% |
-$2.63M +25.0% |
-$3.50M | — | — |
| Shares Outstanding | 7.24M +0.0% |
7.24M +0.0% |
7.24M +0.0% |
7.24M -98.2% |
401.39M +0.0% |
401.39M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$165.4K | +11.4% | +3.9% |
| Diluted EPS | September 30, 2025 | -$0.02 | +33.3% | +0.0% |
| Total Assets | September 30, 2025 | $55.3K | +38.4% | -4.2% |
| Cash and Equivalents | September 30, 2025 | $31.8K | +453.7% | -40.7% |
| Stockholders Equity | September 30, 2025 | -$7.31M | -10.1% | -2.3% |
| R&D Expense | September 30, 2025 | $16.0K | -59.5% | +0.2% |
| Operating Income | September 30, 2025 | -$144.4K | +22.6% | +3.0% |
| Gross Profit | November 30, 2011 | $35.3K | +3266.4% | -65.2% |
| Shares Outstanding | September 30, 2025 | 7.24M | +0.0% | +0.0% |
- Mosaic ImmunoEngineering Inc. reported Net Income of -$922.0 thousand for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed an increase of +8.6% in Net Income compared to the prior fiscal year.
- Mosaic ImmunoEngineering Inc. reported Diluted EPS of $0.13 per share (loss) for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed an increase of +7.1% in Diluted EPS compared to the prior fiscal year.
- Mosaic ImmunoEngineering Inc. reported Total Assets of $141.6 thousand for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed a decrease of -21.1% in Total Assets compared to the prior fiscal year.
- Mosaic ImmunoEngineering Inc. reported Cash and Equivalents of $115.0 thousand for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed a decrease of -26.4% in Cash and Equivalents compared to the prior fiscal year.
- Mosaic ImmunoEngineering Inc. reported Stockholders Equity of -$6.79 million for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed a decrease of -15.6% in Stockholders Equity compared to the prior fiscal year.
- Mosaic ImmunoEngineering Inc. reported R&D Expense of $183.9 thousand for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed a decrease of -57.8% in R&D Expense compared to the prior fiscal year.
- Mosaic ImmunoEngineering Inc. reported Operating Income of -$879.7 thousand for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed an increase of +37.2% in Operating Income compared to the prior fiscal year.
- Mosaic ImmunoEngineering Inc. reported Shares Outstanding of 7.24 million shares for fiscal year 2024.
- Mosaic ImmunoEngineering Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: